Relief Therapeutics Holding Net Income
| RLFTF Stock | USD 1.47 0.05 3.52% |
As of the 12th of February 2026, Relief Therapeutics holds the Variance of 178.68, coefficient of variation of (3,457), and Risk Adjusted Performance of (0.01). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Relief Therapeutics, as well as the relationship between them. Put it differently, you can use this information to find out if the company will indeed mirror its model of past market data, or the prices will eventually revert. We were able to interpolate and analyze data for thirteen technical drivers for Relief Therapeutics, which can be compared to its competitors. Please check Relief Therapeutics information ratio and potential upside to decide if Relief Therapeutics is priced some-what accurately, providing market reflects its current price of 1.47 per share. Please also confirm Relief Therapeutics jensen alpha, which is currently at (0.35) to check out the company can sustain itself at a future point.
Relief Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Relief Therapeutics' valuation are provided below:Relief Therapeutics Holding does not presently have any trending fundamental ratios for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Relief |
Relief Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Relief Therapeutics' otc stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Relief Therapeutics.
| 11/14/2025 |
| 02/12/2026 |
If you would invest 0.00 in Relief Therapeutics on November 14, 2025 and sell it all today you would earn a total of 0.00 from holding Relief Therapeutics Holding or generate 0.0% return on investment in Relief Therapeutics over 90 days. Relief Therapeutics is related to or competes with Rocket Pharmaceuticals, Aura Biosciences, Annexon, Solid Biosciences, Larimar Therapeutics, Altimmune, and Autolus Therapeutics. Relief Therapeutics Holding AG, a biopharmaceutical company, provides patients with therapeutic relief from serious dise... More
Relief Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Relief Therapeutics' otc stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Relief Therapeutics Holding upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.04) | |||
| Maximum Drawdown | 78.78 | |||
| Value At Risk | (18.67) | |||
| Potential Upside | 10.91 |
Relief Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Relief Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Relief Therapeutics' standard deviation. In reality, there are many statistical measures that can use Relief Therapeutics historical prices to predict the future Relief Therapeutics' volatility.| Risk Adjusted Performance | (0.01) | |||
| Jensen Alpha | (0.35) | |||
| Total Risk Alpha | (1.97) | |||
| Treynor Ratio | 0.8309 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Relief Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Relief Therapeutics February 12, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.01) | |||
| Market Risk Adjusted Performance | 0.8409 | |||
| Mean Deviation | 6.78 | |||
| Coefficient Of Variation | (3,457) | |||
| Standard Deviation | 13.37 | |||
| Variance | 178.68 | |||
| Information Ratio | (0.04) | |||
| Jensen Alpha | (0.35) | |||
| Total Risk Alpha | (1.97) | |||
| Treynor Ratio | 0.8309 | |||
| Maximum Drawdown | 78.78 | |||
| Value At Risk | (18.67) | |||
| Potential Upside | 10.91 | |||
| Skewness | 0.4442 | |||
| Kurtosis | 10.68 |
Relief Therapeutics Backtested Returns
Relief Therapeutics maintains Sharpe Ratio (i.e., Efficiency) of -0.0349, which implies the firm had a -0.0349 % return per unit of risk over the last 3 months. Relief Therapeutics exposes twenty-one different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check Relief Therapeutics' Variance of 178.68, risk adjusted performance of (0.01), and Coefficient Of Variation of (3,457) to confirm the risk estimate we provide. The company holds a Beta of -0.48, which implies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Relief Therapeutics are expected to decrease at a much lower rate. During the bear market, Relief Therapeutics is likely to outperform the market. At this point, Relief Therapeutics has a negative expected return of -0.49%. Please make sure to check Relief Therapeutics' potential upside, as well as the relationship between the rate of daily change and period momentum indicator , to decide if Relief Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.39 |
Below average predictability
Relief Therapeutics Holding has below average predictability. Overlapping area represents the amount of predictability between Relief Therapeutics time series from 14th of November 2025 to 29th of December 2025 and 29th of December 2025 to 12th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Relief Therapeutics price movement. The serial correlation of 0.39 indicates that just about 39.0% of current Relief Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.39 | |
| Spearman Rank Test | 0.36 | |
| Residual Average | 0.0 | |
| Price Variance | 0.11 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Relief Therapeutics Holding reported net income of (34.7 Million). This is 110.17% lower than that of the Healthcare sector and 149.55% lower than that of the Biotechnology industry. The net income for all United States stocks is 106.08% higher than that of the company.
Relief Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Relief Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Relief Therapeutics could also be used in its relative valuation, which is a method of valuing Relief Therapeutics by comparing valuation metrics of similar companies.Relief Therapeutics is currently under evaluation in net income category among its peers.
Relief Fundamentals
| Return On Equity | -0.33 | |||
| Return On Asset | -0.12 | |||
| Operating Margin | (5.96) % | |||
| Current Valuation | 102.36 M | |||
| Shares Outstanding | 4.39 B | |||
| Shares Owned By Insiders | 3.68 % | |||
| Shares Owned By Institutions | 22.16 % | |||
| Price To Book | 0.70 X | |||
| Price To Sales | 22.16 X | |||
| Revenue | 3.32 M | |||
| Gross Profit | 2.57 M | |||
| EBITDA | (33.3 M) | |||
| Net Income | (34.7 M) | |||
| Cash And Equivalents | 29.87 M | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 396 K | |||
| Debt To Equity | 0.03 % | |||
| Current Ratio | 2.80 X | |||
| Book Value Per Share | 0.04 X | |||
| Cash Flow From Operations | (35.72 M) | |||
| Earnings Per Share | (0.01) X | |||
| Number Of Employees | 10 | |||
| Beta | -13.71 | |||
| Market Capitalization | 120.99 M | |||
| Total Asset | 251.62 M | |||
| Net Asset | 251.62 M |
About Relief Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Relief Therapeutics Holding's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Relief Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Relief Therapeutics Holding based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in Relief OTC Stock
Relief Therapeutics financial ratios help investors to determine whether Relief OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Relief with respect to the benefits of owning Relief Therapeutics security.